OES said the integration of goniometers and rotary stage enables examination of medical instrument cutting edges and other ...

The Parnassus Growth Equity Fund returned 4.85% (net) for Q4 2024, underperforming the Russell 1000 Growth Index’s 7.07%.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...